Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 30–Sep 6, 2026)

· 1 min read

Here’s what’s on the biotech calendar for August 30–September 6: 0 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies.

🧪 Trial Catalysts & Milestones

  • APGE, 2026-09-01: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity…
  • OSTX, 2026-09-01: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Registry
  • ORIC, 2026-09-01: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Registry
  • ARVN, 2026-09-01: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) Registry
  • BHVN, 2026-09-01: Taldefgrobep Alfa in Adults With Overweight and Obesity Registry
  • BHVN, 2026-09-01: Study of BHV-1300 in Graves' Disease Registry
  • GILD, 2026-09-01: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Registry

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • NUVL: NDA in 19 days, score 61/100
  • CYTK: Phase 2, Recruiting in 2 days, score 59/100
  • SNDX: Phase 2, Active Trial in 2 days, score 50/100

📈 Last Week’s Biggest Gainers

  • BHVN +17.87% (volume 5.5x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.